Articles

1. Spray Drying Enhances Solubility And Bioavailability Of Poorly Soluble Drugs 12/10/2015

   Over the last three decades, improved R&D has provided for modernized spray drying equipment to better meet the necessary requirements to produce powder with tailor-made properties for the end-user.

2. How A Leading Biopharma Manufacturer Is Re-Inventing Its CDMO Business 10/23/2015

   After establishing itself as a leading manufacturer of high purity biopharma components (i.e. supplying product to 6 of the top 10 billion dollar blockbuster biopharma drugs) and valued partner for custom API / HPAPI synthesis for over 80 years, Pfanstiehl became a wholly-owned subsidiary of the Ferro Corporation in 2001.

3. Outsourcing Trends In Small Molecule API Manufacturing 6/30/2014

   Lately, much of the enthusiasm in drug development is centered around large molecule API / biologics. However, the vast majority of drugs on the market, and in development, have a chemical-based, small molecule active ingredient. Considering the dominance of this type of medicine on the market, it is not surprising that one-third of the CMOs included in Nice Insight offer commercial-scale small molecule API and advanced intermediates manufacturing, as compared to 20 percent that offer biologic API manufacturing.

4. Key Criteria When Evaluating A High Potency Manufacturing Outsourcing Partner 4/8/2014

   Many companies are choosing to outsource the manufacture of their highly potent compounds for strategic and/or economic reasons. A provider of contract pharma services in high potent manufacturing, Alkermes Contract Pharma Services, outlines here some of the elements that should be considered by a Sponsor/Donor Pharmaceutical company when outsourcing secondary processing (i.e. dosage form transfer, scale-up and commercial manufacture) of a highly potent product.

5. A Response From India 3/28/2014

   A recent article I wrote for Outsourced Pharma on challenges for the Indian outsourcing industry struck a chord with some readers and elicited some high notes. The “music” came from readers in India as well as other countries, and thankfully was upbeat and progressive for the most part.

   Some of the responses reminded this columnist of parts of a book titled “Rivals,” [1] which was published in 2008 by Bill Emmott. Within the book is a discourse on the Indian economy and its relationship (rivalry) with China. More about the book in a moment.

   To sum up the sentiment from readers in India regarding the current topic and article, this one sentence speaks volumes: “India’s low cost is becoming a problem for the whole country.”

    

   ---

   [1] “Rivals”; Bill Emmott, published by Harcourt, Inc. ; 2008

6. It's A Regional Sale For Contract Research/Manufacturing 2/3/2014

   During the last few weeks I had the opportunity to speak with three experienced and successful business development professionals in the pharmaceutical contract manufacturing arena. They asked to remain anonymous, so I will simply refer to them as Hu, Himani, and Henry. What I got from these discussions with three individuals from three different countries was contrasting views on outsourcing and the future direction of the contract research and manufacturing industry. You can look at these as different world views, or to put it more accurately, different regional views. 

7. Improving Drug Delivery Systems With Novel Emulsion Technologies For Sterile Product Formulation 9/27/2013

   ET4ME type technologies address head on the challenges of large-scale manufacturing/scale-up needs and  convoluted production schemes. Polymer microspheres can be formulated with a highly defined size, encapsulating the API in a polymer matrix.

8. Outsourcing In The Pharma Industry – Experience, Expertise And Enthusiasm 6/13/2012

   2012 will be regarded by many commentators as one of the most challenging years in the pharmaceutical industry’s history, due in no small part to numerous products facing patent expirations and increased global competition.

9. Cytotoxic Formulation & Filling 3/26/2012
   DSM expanded their commercial-scale sterile pharmaceutical services by offering filling and lyophilization of cytotoxic products.
10. Brochure: Finished Dosage Forms 2/21/2012
    DSM is a global provider of finished dosage form manufacturing and related services to pharmaceutical and biopharmaceutical markets.